Satellos Bioscience Inc.
MSCL.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 9.48M | 4.28M | 1.51M | 3.21M | 1.60M |
| Gross Profit | -9.48M | -4.28M | -1.51M | -3.21M | -1.60M |
| SG&A Expenses | 9.43M | 8.83M | 8.03M | 7.52M | 6.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.82M | 30.02M | 26.46M | 24.49M | 22.22M |
| Operating Income | -35.82M | -30.02M | -26.46M | -24.49M | -22.22M |
| Income Before Tax | -34.46M | -28.36M | -24.70M | -21.91M | -22.73M |
| Income Tax Expenses | 154.00K | 142.00K | 172.00K | 114.00K | 95.00K |
| Earnings from Continuing Operations | -34.61 | -28.50 | -24.87 | -22.03 | -22.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.61M | -28.50M | -24.87M | -22.03M | -22.83M |
| EBIT | -35.82M | -30.02M | -26.46M | -24.49M | -22.22M |
| EBITDA | -35.82M | -30.02M | -26.46M | -24.48M | -22.21M |
| EPS Basic | -1.98 | -1.81 | -1.73 | -1.70 | -1.98 |
| Normalized Basic EPS | -1.23 | -1.13 | -1.07 | -1.06 | -1.04 |
| EPS Diluted | -1.98 | -1.81 | -1.73 | -1.70 | -1.98 |
| Normalized Diluted EPS | -1.23 | -1.13 | -1.07 | -1.06 | -1.04 |
| Average Basic Shares Outstanding | 68.68M | 62.11M | 57.50M | 52.07M | 47.55M |
| Average Diluted Shares Outstanding | 68.68M | 62.11M | 57.50M | 52.07M | 47.55M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |